100 related articles for article (PubMed ID: 27168107)
1. Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):13-5. PubMed ID: 27168107
[No Abstract] [Full Text] [Related]
2. Influence of lanreotide on uptake of
Aalbersberg EA; de Wit-van der Veen BJ; Versleijen MWJ; Saveur LJ; Valk GD; Tesselaar MET; Stokkel MPM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):696-703. PubMed ID: 30097670
[TBL] [Abstract][Full Text] [Related]
3. Early Detection of Bone Metastasis in Small Cell Neuroendocrine Carcinoma of the Cervix by 68Ga-DOTATATE PET/CT Imaging.
Damian A; Lago G; Rossi S; Alonso O; Engler H
Clin Nucl Med; 2017 Mar; 42(3):216-217. PubMed ID: 28005640
[TBL] [Abstract][Full Text] [Related]
4. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
[TBL] [Abstract][Full Text] [Related]
5. Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease.
Sharma A; Navaz AJ; Pandey MK; Parent EE
Clin Nucl Med; 2022 Feb; 47(2):137-139. PubMed ID: 34690295
[TBL] [Abstract][Full Text] [Related]
6. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
7. Metastatic neuroendocrine carcinoma presenting as a "Superscan" on 68Ga-DOTANOC somatostatin receptor PET/CT.
Naswa N; Karunanithi S; Soundararajan R; Das KJ; Agarwal KK; Malhotra A; Bal C; Kumar R
Clin Nucl Med; 2012 Sep; 37(9):892-4. PubMed ID: 22889781
[TBL] [Abstract][Full Text] [Related]
8. [Lanreotide++: a new therapeutic option in acromegaly].
Díez JJ
Med Clin (Barc); 1996 Sep; 107(7):257-69. PubMed ID: 8975096
[No Abstract] [Full Text] [Related]
9. Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases.
Mahajan S; Shaha A; Grewal RK
Clin Nucl Med; 2018 Feb; 43(2):136-138. PubMed ID: 29261627
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT.
Kunz WG; Eschbach RS; Stahl R; Kazmierczak PM; Bartenstein P; Rominger A; Auernhammer CJ; Spitzweg C; Ricke J; Cyran CC
Cancer Imaging; 2018 Sep; 18(1):34. PubMed ID: 30236163
[TBL] [Abstract][Full Text] [Related]
11. Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?
Basu S; Adnan A
Nucl Med Commun; 2019 Oct; 40(10):1086-1087. PubMed ID: 31365493
[No Abstract] [Full Text] [Related]
12. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?
Basu S; Ostwal V
Nucl Med Commun; 2016 Jun; 37(6):669-71. PubMed ID: 27105440
[No Abstract] [Full Text] [Related]
13. Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.
Kunikowska J; Ziemnicka K; Pawlak D; Ruchała M; Kolasa A; Janicka-Jedyńska M; Woźniak A; Mikołajczak R; Królicki L
Endokrynol Pol; 2016; 67(1):68-71. PubMed ID: 26884118
[TBL] [Abstract][Full Text] [Related]
14. Brain Metastasis of Medullary Thyroid Carcinoma Without Macroscopic Calcification Detected First on 68Ga-Dotatate and Then on 18F-Fluoride PET/CT.
Duarte PS; Marin JFG; De Carvalho JWA; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):623-624. PubMed ID: 29894334
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
16. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience.
Win Z; Al-Nahhas A; Towey D; Todd JF; Rubello D; Lewington V; Gishen P
Nucl Med Commun; 2007 May; 28(5):359-63. PubMed ID: 17414885
[TBL] [Abstract][Full Text] [Related]
18. Two Abdominal Masses Detected With
Grazia Giancipoli R; Khattar P; Bodei L
Gastroenterology; 2018 Oct; 155(4):e11-e13. PubMed ID: 29883581
[No Abstract] [Full Text] [Related]
19. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
[TBL] [Abstract][Full Text] [Related]
20. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
